LogicBio Therapeutics, Inc. (LOGC) News
Filter LOGC News Items
LOGC News Results
|Loading, please wait...|
LOGC News Highlights
- LOGC's 30 day story count now stands at 5.
- Over the past 7 days, the trend for LOGC's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- MSCI, BIO and DRUG are the most mentioned tickers in articles about LOGC.
Latest LOGC News From Around the Web
Below are the latest news stories about LogicBio Therapeutics Inc that investors may wish to consider to help them evaluate LOGC as an investment opportunity.
Gainers: Palisade Bio (NASDAQ:PALI) +23%. Pharming Group (NASDAQ:PHAR) +14%. Entasis Therapeutics (NASDAQ:ETTX) +13%. Epizyme (NASDAQ:EPZM) +11%. IceCure Medical (NASDAQ:ICCM) +10%. Losers: LogicBio Therapeutics (NASDAQ:LOGC) -50%. Pardes Biosciences (NASDAQ:PRDS) -13%. Biofrontera (NASDAQ:BFRI) -12%. Midatech Pharma (NASDAQ:MTP) -11%. Hyperfine (NASDAQ:HYPR) -7%....
Good morning, investor!
The FDA ordered the clinical hold after two of the four patients who had been dosed in the trial developed severe blood reactions.
The FDA has placed a clinical hold on LogicBio Therapeutics Inc's (NASDAQ: LOGC) Phase 1/2 SUNRISE trial of LB-001 in pediatric patients with methylmalonic acidemia (MMA). The hold follows after two adolescent patients in the trial were diagnosed with thrombotic microangiopathy (TMA), a clinical syndrome defined by the formation of tiny clots in blood vessels. The Company is evaluating LB-001 in a Phase 1/2 trial to treat children with the rare metabolic disease methylmalonic acidemia, which res
LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today provided an update on the LB-001 clinical development program. The U.S. Food and Drug Administration (FDA) has notified the company that its Phase 1/2 SUNRISE clinical trial of LB-001 in pediatric patients with methylmalonic acidemia (MMA) has been placed on clinical hold. The company will host a conference call and webcast this morning to discuss this update.
Investment company Independence Bank of Kentucky (Current Portfolio) buys PayPal Holdings Inc, iShares S&P Global Clean Energy Index Fund, Activision Blizzard Inc, Altria Group Inc, General Motors Co, sells iShares MSCI Emerging Markets ETF, Vanguard Long-Term Government Bond ETF, AT&T Inc, BTC iShares MSCI USA Min Vol Factor ETF, Waste Management Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Independence Bank of Kentucky.
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Fred Chereau, will participate in a fireside chat at the virtual H.C. Wainwright Bioconnect Conference being held January 10-13, 2022. The pre-recorded presentation will be available for on-demand viewing beginning at 7:00 a.m. ET on Monday, January 10, 2022.
LogicBio Therapeutics (NASDAQ:LOGC) had its target price lowered by Chardan Capital from $20.00 to $16.00 in a research note issued to investors on Thursday morning, PriceTargets.com reports. The brokerage currently has a buy rating on the stock. LOGC has been the topic of several other reports. Zacks Investment Research cut LogicBio Therapeutics from a hold 
H.C. Wainwright analyst Edwin Zhang maintained a Buy rating on Logicbio Therapeutics (LOGC – Research Report) today and set a price target of $15.00. The company's shares closed last Wednesday at $2.33. According to TipRanks.com, Zhang has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -22.9% and a 11.1% success rate. Zhang covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Calliditas Therapeutics, and Reneo Pharmaceuticals. Currently, the analyst consensus on Logicbio Therapeutics is a Strong Buy with an average price target of $13.00. See the top stocks recommended by analysts >> The company has a one-year high of $9.
LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today provided updates around its SUNRISE Phase 1/2 clinical trial and development pipeline, and announced the appointment of Susan R. Kahn to its Board of Directors.